MAP3K8
Reactivity: Human, Rat, Mouse
WB, ELISA, IHC (p), IF (cc), IF (p), IHC (fro), FACS
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA: 1/1,000. Western blotting: 1/100 - 1/500. Immunohistochemistry: 1/50 - 1/100. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Target
MAP3K8
(Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))
COT, a member of the MAPKKK subfamily of Ser/Thr protein kinases, is able to activate NF-kappa-B 1 by stimulating proteasome-mediated proteolysis of NF-kappa-B 1/p105. It plays a role in the cell cycle. The longer form of cot has some transforming activity, although it is much weaker than the activated cot oncoprotein. This cytoplasmic protein is expressed in several normal tissues and human tumor-derived cell lines. The 58 kDa form is activated specifically during the S and G2/M phases of the cell cycle. The longer form undergoes phosphorylation on Ser residues mainly, and the shorter form on both Ser and Thr residues.Synonyms: COT, COT proto-oncogene serine/threonine-protein kinase, Cancer Osaka thyroid oncogene, ESTF, MAPK, Mitogen-activated protein kinase kinase kinase 8, Tumor progression locus 2, Tumor progression locus 2